New HIV/AIDS data have been reported by P.S. Belperio and co-authors
2009 JUL 13 - (NewsRx.com) -- "The Veterans Health Administration (VHA) develops guidelines for VHA providers that delineate specific criteria for use of certain complex, costly medications indicated for specialized populations," scientists in the United States report. "These criteria are disseminated to all VHA facilities. To (a) assess the concordance with VHA guidelines for use of 4 antiretrovirals (atazanavir, darunavir, entuvirtide, and tipranavir), and (b) to describe prescribing of these agents before and after implementation of the guideline criteria," wrote P.S. Belperio and colleagues. The researchers concluded: "In this retrospective cohort study, we evaluated all veterans in VHA care who received their first outpatient prescription for a target antiretroviral between its FDA approval date and December 31, 2007, using outpatient prescription records obtained from the VHA Human Immunodeficiency Virus (HIV) Clinical Case Registry (CCR:HIV), an observational registry database created through extraction of specific clinical data from the VHA's electronic medical record." Belperio and colleagues published their study in the Journal of Managed Care Pharmacy (Provider Prescribing of 4 Antiretroviral Agents After Implementation of Drug Use Guidelines in the Department of Veterans Affairs. Journal of Managed Care Pharmacy, 2009;15(4):323-334). For additional information, contact P.S. Belperio, Center Qual Management Public Health, Dept. of Vet. Affairs, HIV & HCV Clinic Case Registry, 3801 Miranda Avenue M-C 132, Palo Alto, CA 94304, USA. The publisher's contact information for the Journal of Managed Care Pharmacy is: Acad Managed Care Pharmacy, 100 N Pitt St., 400, Alexandria, VA 22314-3134, USA. Keywords: United States, Palo Alto, HIV/AIDS, AIDS, Acquired Immune Deficiency Syndrome, Acquired Immunodeficiency Syndrome, Anti-HIV, Antivirals, Atazanavir, Clinical Trial Research, Darunavir, Drugs, FDA, HIV, Human Immunodeficiency Virus, Immunology, Managed Care, Pharmaceuticals, Protease Inhibitor, Sexually Transmitted Disease, Therapy, Tipranavir, Treatment, U.S. Food and Drug Administration, Viral, Virology. This article was prepared by AIDS Weekly editors from staff and other reports. Copyright 2009, AIDS Weekly via NewsRx.com.
|
